Literature DB >> 19333224

Surgery: selective bladder-preserving therapy for muscle-invasive cancer.

Niall M Heney1, Donald S Kaufman, William U Shipley.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19333224     DOI: 10.1038/nrclinonc.2009.21

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.

Authors:  A L Zietman; J Grocela; E Zehr; D S Kaufman; R H Young; A F Althausen; N M Heney; W U Shipley
Journal:  Urology       Date:  2001-09       Impact factor: 2.649

2.  Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.

Authors:  M H Hussain; T R Glass; J Forman; W Sakr; D C Smith; M Al-Sarraf; J Jones; S P Balcerzak; E D Crawford; H B Grossman
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

3.  Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.

Authors:  W U Shipley; D S Kaufman; E Zehr; N M Heney; S C Lane; H K Thakral; A F Althausen; A L Zietman
Journal:  Urology       Date:  2002-07       Impact factor: 2.649

4.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

5.  Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

Authors:  Donald S Kaufman; Kathryn A Winter; William U Shipley; Niall M Heney; H James Wallace; Leonard M Toonkel; Anthony L Zietman; Simon Tanguay; Howard M Sandler
Journal:  Urology       Date:  2008-12-18       Impact factor: 2.649

6.  Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors.

Authors:  Anthony L Zietman; Dianne Sacco; Uri Skowronski; Pablo Gomery; Donald S Kaufman; Jack A Clark; James A Talcott; William U Shipley
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

7.  Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.

Authors:  W U Shipley; K A Winter; D S Kaufman; W R Lee; N M Heney; W R Tester; B J Donnelly; P M Venner; C A Perez; K J Murray; R S Doggett; L D True
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

8.  Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival.

Authors:  W U Shipley; M A Rose; T L Perrone; C M Mannix; N M Heney; G R Prout
Journal:  J Urol       Date:  1985-10       Impact factor: 7.450

  8 in total
  2 in total

1.  Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.

Authors:  Timur Mitin; Asha George; Anthony L Zietman; Niall M Heney; Donald S Kaufman; Robert G Uzzo; Robert Dreicer; H James Wallace; Luis Souhami; M Chris Dobelbower; Howard M Sandler; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-09-28       Impact factor: 7.038

2.  Imatinib radiosensitizes bladder cancer by targeting homologous recombination.

Authors:  Boling Qiao; Martin Kerr; Blaz Groselj; Mark T W Teo; Margaret A Knowles; Robert G Bristow; Roger M Phillips; Anne E Kiltie
Journal:  Cancer Res       Date:  2013-01-09       Impact factor: 12.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.